natgillin/translations-raw huggingface dataset:
Haemodynamic parameters: These were assessed in STRIDE-1 for both functional class II and III patients.
V STRIDE-1 so ocenjevali hemodinamične parametre za bolnike II. in III. razreda.
Haemodynamic studies and exercise based controlled clinical trials in NYHA Class II-IV heart failure patients have shown that amlodipine did not lead to clinical deterioration as measured by exercise tolerance, left ventricular ejection fraction and clinical symptomatology.
V študijah o hemodinamiki in nadzorovanih kliničnih preskušanjih z obremenitvijo, v katerih so sodelovali bolniki s srčnim popuščanjem II. do IV. stopnje po NYHA, se po dajanju amlodipina klinično stanje bolnikov ni poslabšalo, kar so pokazale meritve prenašanja napora, iztisne frakcije levega prekata in klinična simptomatika.
Haemoglobin <11 g/dl at baseline to >11 g/dl post baseline
Hemoglobin < 11 g/dl izhodiščno do > 11 g/dl poizhodiščno
Haemoglobin A1c –Reduction
Hemoglobin A1c – zmanjšanje1
Haemoglobin Adult: ≥ 12 g/dl (females); ≥ 13 g/dl (males)
Hemoglobin Odrasli ≥12 g/dl (ženske); ≥13 g/dl (moški)
Haemoglobin Adults: ≥ 12 g/dl (females); ≥ 13 g/dl (males)
Hemoglobin Odrasli: ≥ 12 g/dl (ženske); ≥ 13 g/dl (moški)
Haemoglobin and haematocrit decreased
znižana vrednost hemoglobina in hematokrita
Haemoglobin and haematocrit: Small decreases in haemoglobin and haematocrit (mean decreases of approximately 0.05 mmol/l and 0.16 volume percent, respectively) were observed.
Hemoglobin in hematokrit: Opažali so majhno znižanje vrednosti hemoglobina in hematokrita (povprečno znižanje koncentracije hemoglobina za približno 0,05 mmol/l in hematokrita za
Haemoglobin concentration and platelet counts were evaluated as changes from baseline, which was defined as the end of the patient’s treatment with imiglucerase.
Koncentracijo hemoglobina in število trombocitov so ocenili kot spremembo glede na izhodiščno vrednost, ki je bila opredeljena kot vrednost ob koncu bolnikovega zdravljenja z imiglucerazo.
Haemoglobin concentrations were corrected to ≥ 10 g/dl in > 98% (p < 0.001) of paediatric patients administered darbepoetin alfa once weekly and 84% (p = 0.293) once every two weeks.
Koncentracija hemoglobina se je popravila na ≥ 10 g/dl pri > 98 % (p < 0,001) pediatričnih bolnikov, ki so dobivali darbepoetin alfa vsak teden, in pri 84 % (p = 0,293) tistih, ki so ga dobivali vsaka dva tedna.
Haemoglobin decrease (rarely resulting in anaemia), haematocrit decrease
Znižanje hemoglobina (ki redko povzroči anemijo), znižanje hematokrita
Haemoglobin decreased
hemoglobina
Haemoglobin decreased
zmanjšana vrednost hemoglobina
Haemoglobin decreased
zmanjšanje vrednosti hemoglobina
Haemoglobin decreased
znižana vrednost hemoglobina
Haemoglobin decreased
znižane vrednosti hemoglobina
Haemoglobin decreased
znižanje hemoglobina
haemoglobin decreased heart rate increased
zmanjšanje koncentracije hemoglobina zvišanje srčnega utripa
Haemoglobin decreased White blood cell count decreased
znižana raven hemoglobina zmanjšano število levkocitov
Haemoglobin decreased, blood uric acid increased, hepatic enzyme increased, blood creatine phosphokinase increased
Redki: znižana raven hemoglobina, zvišana raven sečne kisline v krvi, zvišana raven jetrnih encimov, zvišana raven kreatin-fosfokinaze v krvi
Haemoglobin decreased, blood uric acid increased, hepatic enzyme increased, blood creatine phosphokinase increased,
Redki: znižana raven hemoglobina, zvišana raven sečne kisline v krvi, zvišana raven jetrnih encimov, zvišana raven kreatin-fosfokinaze v krvi
Haemoglobin decreased, haematocrit decreased
znižana vrednost hemoglobina, znižana vrednost hematokrita
Haemoglobin decreased, haematocrit decreased, blood creatinine increased
znižana vrednost hemoglobina, znižana vrednost hematokrita, zvišana vrednost kreatinina v krvi
haemoglobin decreased, haematocrit decreased, white blood cell count decreased
znižanje hemoglobina, znižanje hematokrita, zmanjšano število levkocitov
Haemoglobin decreased, White blood cell count decreased
znižanje ravni hemoglobina, zmanjšano število belih krvničk
Haemoglobin decreaseda, haematocrit decreaseda, blood creatinine increaseda
znižana vrednost hemoglobinaa, znižana vrednost hematokritaa, zvišana vrednost kreatinina v krvia
Haemoglobin decreaseda, haematocrit decreaseda, blood creatinine increaseda, glycosuriah
angioedema, rdečinaa, fotosenzitivne reakcijeh
Haemoglobin decreaseda, haematocrit decreaseda, blood creatinine increaseda, glycosuriah
znižana vrednost hemoglobinaa, znižana vrednost hematokritaa, zvišana vrednost kreatinina v krvia, glikozurijah
Haemoglobin drop*
Zmanjšanje vrednosti hemoglobina
Haemoglobin glutamer-200 (bovine) – 130 mg/ml
Hemoglobin glutamer-200 (goveji) – 130 mg/ml
Haemoglobin glutamer-200 (bovine) – 130 mg/ml.
Hemoglobin glutamer-200 (goveji) – 130 mg/ml
Haemoglobin in patients with history of stable cardiac disease
Hemoglobin pri bolnikih s stabilno boleznijo srca v anamnezi
Haemoglobin in subjects with history of stable cardiac disease
Hemoglobin pri osebah s stabilno boleznijo srca v anamnezi
Haemoglobin increase > 15 g/L (0.9 mmol/L) at Week 13/haemoglobin response-evaluable population
zvišanje koncentraije hemoglobina na > 15 g/l (0,9 mmol/l) po 13 tednih pri populaciji s podatkom okoncentraciji hemoglobina
Haemoglobin is the protein in red blood cells that carries oxygen around the body.
Hemoglobin je beljakovina v rdečih krvnih celicah, ki
Haemoglobin is the protein in red blood cells that carries oxygen around the body.
Hemoglobin je beljakovina v rdečih krvničkah, ki prenaša kisik po telesu.
Haemoglobin Level
Raven hemoglobina
Haemoglobin Level (g/dL)
Raven hemoglobina (g/dl)
Haemoglobin levels
Koncentracija hemoglobina
Haemoglobin levels dropped below 10 g/dL in up to 14 % of adult patients and 7 % of children and adolescents treated with ribavirin in combination with either peginterferon alfa-2b or interferon alfa- 2b.
Pri do 14 % odraslih bolnikov in 7 % otrok in mladostnikov, zdravljenih z ribavirinom v kombinaciji bodisi s peginterferonom alfa-2b ali z interferonom alfa-2b, se je vrednost hemoglobina znižala pod 10 g/dl.
Haemoglobin levels dropped below 10 g/dl in up to 14 % of adult patients and 7 % of children and adolescents treated with ribavirin in combination with either peginterferon alfa-2b or interferon alfa-2b.
Pri do 14 % odraslih bolnikov in 7 % otrok in mladostnikov, zdravljenih z ribavirinom v kombinaciji bodisi s peginterferonom alfa-2b ali z interferonom alfa-2b, se je vrednost hemoglobina znižala pod 10 g/dl.
Haemoglobin levels dropped below 10 g/dl in up to 14% of adult patients and 7% of children and adolescents treated with ribavirin in combination with either peginterferon alfa-2b or interferon alfa- 2b.
Pri do 14 % odraslih bolnikov in 7 % otrok in mladostnikov, zdravljenih z ribavirinom v kombinaciji bodisi s peginterferonom alfa-2b ali z interferonom alfa-2b, se je vrednost hemoglobina znižala pod 10 g/dl.
Haemoglobin or haematocrit should be monitored before initiation of, and periodically throughout, treatment with axitinib.
Raven hemoglobina ali hematokrita je treba spremljati pred začetkom zdravljenja z aksitinibom in v rednih časovnih presledkih med njim.
Haemoglobin variability should be addressed through dose management with consideration for the haemoglobin target range of 10 g/dl (6.2 mmol/l) to 12 g/dl (7.5 mmol/l).
Zaradi variabilnosti koncentracij hemoglobina pri posameznikih je treba odmerek prilagoditi, pri tem pa upoštevati ciljni razpon hemoglobina od 10 g/dl (6,2 mmol/l) do 12 g/dl (7,5 mmol/l).
Haemoglobin variability should be addressed through dose management, with consideration for the desired haemoglobin concentration range between 10 g/dl (6.2 mmol/l) to 12 g/dl (7.5 mmol/l).
Nihanja hemoglobina je treba obravnavati s prilagajanjem odmerka, pri tem pa je treba upoštevati želeni razpon koncentracije hemoglobina med 10 g/dl (6,2 mmol/l) in 12 g/dl (7,5 mmol/l).
Haemoglobin variability should be addressed through dose management, with consideration for the haemoglobin concentration range of 10 g/dl (6.2 mmol/l) to 12 g/dl (7.5 mmol/l).
Na razlike v hemoglobinu se je treba odzvati z določanjem odmerka ob upoštevanju razpona koncentracije hemoglobina od 10 g/dl (6,2 mmol/l) do 12 g/dl (7,5 mmol/l).
Haemoglobin variability should be addressed through dose management, with consideration for the haemoglobin target range of 10 g/dL (6.2 mmol/l) to 12 g/dl (7.5 mmol/l).
V primeru odstopanja vrednosti hemoglobina je treba prilagoditi odmerek, pri tem pa upoštevati ciljni razpon koncentracij hemoglobina od 10 g/dl (6,2 mmol/l) do 12 g/dl (7,5 mmol/l).
Haemoglobin variability should be addressed through dose management, with consideration for the haemoglobin target range of 10 g/dl (6.21 mmol/l) to 12 g/dl (7.45 mmol/l).
Razlike v koncentraciji hemoglobina urejamo z uravnavanjem odmerkov, pri čemer upoštevamo, da je ciljno območje koncentracije hemoglobina od 10 g/dl (6,21 mmol/l) do 12 g/dl (7,45 mmol/l).
Haemoglobin variability should be addressed through dose management, with consideration for the haemoglobin target range of 10 g/dl (6.21 mmol/l) to 12 g/dl (7.45 mmol/l).
Te razlike vrednosti hemoglobina je treba obravnavati, tako da se spreminja odmerek, pri čemer je treba upoštevati razpon hemoglobina od 10 g/dl (6,21 mmol/l) do 12 g/dl (7,45 mmol/l).
Haemoglobin ≥ 8 g/dL
Koncentracija hemoglobina ≥ 8 g/dl (80 g/l).
Haemoglobin ≥ 8 g/dl
Koncentracija hemoglobina ≥ 8 g/dl.
Haemoglobin: ≥ 12 g/dl (females); ≥ 13 g/dl (males)
hemoglobin: ≥ 120 g/l (ženske); ≥ 130 g/l (moški)
Haemoglobina
hemoglobina
Haemoglobinopathies (e.g., thalassemia, sickle-cell anaemia).
Hemoglobinopatije (npr. talasemija, anemija srpastih celic)
Haemoglobinopathies (e.g., thalassemia, sickle-cell anaemia).
Hemoglobinopatije (npr. talasemija, anemija srpastih celic);
Haemolysis
hemoliza
Haemolysis (breakdown of red blood cells) is an uncommon side effect in patients given human normal immunoglobulin (occurring with less than 1 dose in 100).
Redek neželeni učinek pri bolnikih, ki prejemajo humani polispecifični imunoglobulin (ki se pojavi pri manj kot 1 od 100 odmerkov), je hemoliza (razkroj eritrocitov).
Haemolysis, Autoimmune haemolytic anaemia, Haemolytic anaemia
hemoliza, avtoimuna hemolitična anemija, hemolitična anemija
Haemolytic
hemolitična
Haemolytic activity during the course of the study was effectively blocked in both female and male mice.
Hemoliza je bila med trajanjem študije praktično zaustavljena tako pri mišjih samicah kot samcih.
Haemolytic anaemia
hemolitična anemija
Haemolytic anaemia
hemolitična anemija methemoglobine mija
Haemolytic anaemia can develop subsequent to IVIg therapy due to enhanced RBC sequestration.
Hemolitična anemija se lahko razvije po zdravljenju z i.v. imunoglobulini zaradi večje sekvestracije eritrocitov.
Haemolytic anaemia can develop subsequent to IVIg therapy due to enhanced red blood cells (RBC) sequestration.
Hemolitična anemija se lahko pojavi po zdravljenju z zdravili i.v.
Haemolytic anaemia has also been reported in case of severe overdose (20-30 mg/kg) in infants and adults with methaemoglobinaemia caused by aniline or chlorates.
O hemolitični anemiji so poročali tudi v primeru znatno prevelikega odmerjanja (20–30 mg/kg) pri dojenčkih in odraslih z methemoglobinemijo, povzročeno z anilinom ali klorati.
haemolytic anaemia, haemolysis (see section 4.4)
hemolitična anemija, hemoliza (glejte poglavje 4.4)
Haemolytic anaemia: If you have an inherited condition where your red blood cells don’t produce enough of the enzyme G6PD, Avaglim may cause your red blood cells to be destroyed too quickly (haemolytic anaemia).
Hemolitična anemija: Če veste, da vaše rdeče krvne celice ne proizvajajo dovolj encima glukoze-6-fosfat-dehidrohenaze (G6PD), če boste jemali Avaglim, bi lahko tvegali, da boste zboleli za resnim tipom anemije, ker se vaše rdeče krvničke prehitro razkrojijo (hemolitična anemija).
haemolytic anaemiab, thrombocytopenia, eosinophilia, neutropenia
hemolitična anemijab, trombocitopenija, eozinofilija, nevtropenija
haemolytic uraemic syndrome, thrombotic
hemolitično uremični sindrom, trombotična
haemolytic uraemic syndrome, thrombotic thrombocytopenic
hemolitično-uremični sindrom, trombotična
Haemolytic uraemic syndrome; Neutropaenia
hemolitično-uremični sindrom, nevtropenija
Haemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) has been uncommonly reported in the setting of CRS.
Občasno so v okviru sindroma sproščanja citokinov poročali o sindromu hemofagocitne limfohistiocitoze/aktivacije makrofagov.
Haemophilia A is a X-linked hereditary disorder of blood coagulation due to decreased levels of functional factor VIII and results in bleeding into joints, muscles or internal organs, either spontaneously or as a result of accidental or surgical trauma.
Hemofilija A je na kromosom X vezana dedna motnja strjevanja krvi zaradi znižanih ravni funkcionalnega faktorja VIII in povzroči krvavitev v sklepe, mišice ali notranje organe, bodisi spontano ali kot posledica nezgode ali kirurške poškodbe.
haemophilia A,
hemofilija A,
Haemophilia B is an X-linked hereditary disorder of blood coagulation due to decreased levels of factor IX and results in bleeding into joints, muscles or internal organs, either spontaneously or as a result of accidental or surgical trauma.
Hemofilija B je na kromosom X vezana dedna motnja strjevanja krvi zaradi znižanih ravni faktorja IX in povzroči krvavitev v sklepe, mišice ali notranje organe, bodisi spontano ali kot posledica nezgode ali kirurške poškodbe.
Haemophilia B patients may develop antibodies (inhibitors) to factor IX.
Pri bolnikih s hemofilijo B se lahko pojavijo protitelesa (inhibitorji) proti faktorju IX.
Haemophilia type A and B as Kaletra might increase the risk of bleeding.
hemofilijo tipa A in B, ker zdravilo Kaletra lahko zviša tveganje za krvavitve.
Haemophilia type A and B as lopinavir/ritonavir might increase the risk of bleeding.
hemofilijo tipa A in B, ker lopinavir/ritonavir lahko zviša tveganje za krvavitve;
Haemophilia, as there have been reports of increased bleeding in patients with haemophilia who are taking this type of medicine (protease inhibitors).
hemofilijo, opisani so primeri večjih krvavitev pri bolnikih s hemofilijo, ki so jemali to vrsto zdravil (zaviralce proteaz).
Haemophiliac patients
Hemofiliki
Haemophiliac patients should, therefore, be made aware of the possibility of increased bleeding.
Bolnike s hemofilijo je treba seznaniti z možnostjo, da se zveča nagnjenost h krvavitvam.
Haemophiliacs may bleed more
Pri bolnikih s hemofilijo se lahko pojavijo hujše krvavitve
Haemophilus b Conjugate (Meningococcal Protein Conjugate) and Hepatitis B (recombinant) Vaccine.
Konjugirano cepivo proti hemofilusu b (meningokokni beljakovinski konjugat) in rekombinantno cepivo proti hepatitisu B
Haemophilus influenzae polysaccharide type b 12 µg conjugated to tetanus protein (PRP-T) 24 µg
konjugiran na tetanusni toksoid (PRP-T) 24 µg
Haemophilus influenzae type b (Hib): can cause brain swelling (inflammation).
Haemophilus influenzae tipa b (Hib): lahko povzroča oteklino možganov (vnetje).
Haemophilus influenzae type b (HIB): HIB infection most frequently causes brain inflammation (swelling).
Haemophilus influenzae tipa b (HIB): Okužba s HIB najpogosteje povzroči vnetje možgan (oteklino).
Haemophilus influenzae type b (HIB): HIB infection most frequently causes brain inflammation (swelling).
Haemophilus influenzae tipa b (HIB): Okužba s HIB najpogosteje povzroči vnetje možganov (oteklino).
Haemophilus influenzae type b conjugated to tetanus toxoid.................
Haemophilus influenzae tipa b konjugiran na tetanusni toksoid ............
Haemophilus influenzae type b conjugated to tetanus toxoid.................12 µg
Haemophilus influenzae tipa b konjugiran na tetanusni toksoid ............
Haemophilus influenzae type b infections (often just called Hib infections ): serious bacterial infections causing meningitis (inflammation of the outer covering of the brain), which can lead to brain damage, deafness, epilepsy, or partial blindness.
Okužbe s Haemophilusom influenzae tipa b (imenovane tudi okužbe s Hib): hude bakterijske okužbe, ki povzročajo meningitis (vnetje zunanje možganske ovojnice), kar lahko privede do poškodb možganov, gluhosti, epilepsije ali delne slepote.
Haemophilus influenzae type b infections (often just called Hib) are serious bacterial infections and can cause meningitis (inflammation of the outer covering of the brain), which can lead to brain damage, deafness, epilepsy, or partial blindness.
Okužbe s Haemophilusom influenzae tipa b (pogosto imenovan Hib) so hude bakterijske okužbe in lahko povzročajo meningitis (vnetje zunanje možganske ovojnice), kar lahko privede do poškodb možganov, gluhosti, epilepsije ali delne slepote.
Haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) 12 micrograms conjugated to tetanus toxoid (24 micrograms)
Polisaharid Haemophilus influenzae tipa b (poliribozilribitol fosfat) 12 mikrogramov, konjugiran na tetanusni toksoid (24 mikrogramov)
Haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) 12 micrograms conjugated to tetanus toxoid (24 micrograms) for one adjuvanted dose of 0.5 ml
Polisaharid Haemophilus influenzae tipa b (poliribozilribitol fosfat) 12 mikrogramov, konjugiran na toksoid tetanusa (24 mikrogramov) na en 0,5 mililitrski odmerek z adjuvansom
Haemophilus influenzae type b polysaccharide (Polyribosylribitol Phosphate) 3 micrograms Conjugated to meningococcal protein2 50 micrograms
konjugiran na meningokokno beljakovino2 50 mikrogramov
Haemophilus influenzae type b polysaccharide 10 micrograms (polyribosylribitol phosphate)3 conjugated to tetanus toxoid as carrier protein approximately 25 micrograms
polisaharid hemofilusa influence tipa b 10 mikrogramov (poliribozilribitol-fosfat)3 vezan na tetanusni toksoid kot nosilni protein približno 25 mikrogramov
Haemophilus influenzae type b polysaccharide 12 micrograms (Polyribosylribitol Phosphate) conjugated to Tetanus protein 22-36 micrograms
polisaharid hemofilusa influence tipa b 12 mikrogramov (poliribozilribitol fosfat) konjugiran na tetanusno beljakovino 22–36 mikrogramov
Haemophilus influenzae type b polysaccharide conjugated to Tetanus protein
polisaharid hemofilusa influence tipa b
Haemophilus influenzae: S ≤ 0.5 mg/L and R > 0.5 mg/L
Haemophilus influenzae: S ≤ 0,5 mg/l in R > 0,5 mg/l
Haemoptysis Dyspnoea exertional Oropharyngeal painn Nasal congestion Nasal dryness
dispneja med naporom ustno-žrelna bolečinan zamašenost nosu suhost nosu
Haemoptysis may also be indicative of ITP (see above), and an appropriate differential diagnosis has to be undertaken.
Hemoptiza lahko kaže tudi na ITP (glejte zgoraj), zato je treba opraviti ustrezno diferencialno diagnostiko.
Haemoptysis, pulmonary embolism
hemoptiza, pljučna embolija
Haemoptysise
hemoptizae
Haemoptysise
plenomegalijaa
Haemoptysise
psevdoputikaa
Haemorrage, duodenal ulcer, gastritis, dysphagia, dry mouth
krvavitev, razjeda na dvanajstniku, gastritis, disfagija, suha usta
Haemorrhage
(% ali i.e./dl)
Haemorrhage
Blæðing
haemorrhage
kožne krvavitve
Haemorrhage
Krvavitev
Haemorrhage
krvavitev,
Haemorrhage
krvavitevb
Haemorrhage
krvavitevd
haemorrhage
mrežnične krvavitve
Haemorrhage (1)
krvavitev (1)
haemorrhage (at
Krvavitve
haemorrhage (bleeding) raised liver enzymes (hence the need for regular blood tests).
hemoragija (krvavitev) zvečanje jetrnih encimov (zato so potrebne redne preiskave krvi).
Haemorrhage (see section 4.4)
Krvavitev (glejte poglavje 4.4)
Haemorrhage and thrombocytopenia
Krvavitev in trombocitopenija
Haemorrhage b, hypertension
krvavitev b, hipertenzija
Haemorrhage Embolism
krvavitev embolija
Haemorrhage Haematosperm ia
penilna hemoragija hematospermija
Haemorrhage Haematospermi a
penilna hemoragija hematospermija
Haemorrhage in the elderly
Krvavitev pri starejših
Haemorrhage intracranial d *
intrakranialna krvavitevd
haemorrhage or bleeding (any site), hypercoagulation (including thrombophlebitis, pulmonary embolism), syncope, oedema (including peripheral, facial), ecchymoses (including haematoma, petechiae)
krvavitev (na različnih mestih), hiperkoagulacija (vključno s tromboflebitisom in pljučno embolijo), sinkopa, edem (vključno s perifernim in facialnim edemom), ehimoze (vključno s hematomom in petehijami)
haemorrhage raised liver enzymes (hence the need for regular blood tests)
krvavitev zvečanje jetrnih encimov (zato so potrebne redne preiskave krvi).
haemorrhage raised liver enzymes (hence the need for regular blood tests).
krvavitev zvečanje jetrnih encimov (zato so potrebne redne preiskave krvi).
haemorrhage raised liver enzymes (hence the need for regular blood tests).
krvavitev, zvečanje jetrnih encimov (zato so potrebne redne preiskave krvi).
haemorrhage raised liver enzymes (hence the need for regular blood tests).
krvavitev; povišanje ravni jetrnih encimov (zato so potrebne redne preiskave krvi).
Haemorrhage subcutaneous
podkožna krvavitev
Haemorrhage urinary tract
krvavitev v sečilih
Haemorrhage urinary tract h
krvavitev v sečila h
Haemorrhage urinary tract, e Acute renal failure (renal failure)
krvavitev v sečilihe, akutna ledvična odpoved (ledvična odpoved)
Haemorrhage while thrombocytopenic
krvavitev med trombocitopenijo
haemorrhage with fatal
krvavitev (opisani so
haemorrhage with fatal
primeri s smrtnim
haemorrhage with fatal
Retroperitonealna krvavitev
haemorrhage),
krvavitev),
haemorrhage),
lokalno oteklino
Haemorrhage* Hypertension
krvavitev* hipertenzija
haemorrhage*d
krvavitve*d
haemorrhage,
krvavitev
haemorrhage,
krvavitev mrežnice,
haemorrhage, and may
gastralgija (glejte
haemorrhage, and may
krvavitvijo.
Haemorrhage, deep venous thrombosis, oedema leg
krvavitev, globoka venska tromboza, edem nog
Haemorrhage, deep venous thrombosis, oedema leg
krvavitev, globoka venska tromboza, edem noge
Haemorrhage, deep venous thrombosis, oedema leg
krvavitve, edem, edem nog
Haemorrhage, deep venous thrombosis, oedema leg
krvavitve, globoka venska tromboza, edem nog
Haemorrhage, duodenal ulcer, gastritis, dysphagia, dry mouth
krvavitev, razjeda na dvanajstniku, gastritis, disfagija, suha usta
Haemorrhage, haematoma
krvavitve, hematomi
Haemorrhage, including cerebral, gastrointestinal and pulmonary haemorrhage, has been reported and may be associated with a fatal outcome (see section 4.4).
Poročali so o krvavitvi, vključno s cerebralno, gastrointestinalno in pulmonarno krvavitvijo, ki je lahko smrtna. (glejte poglavje 4.4).
Haemorrhage, oedema, oedema leg
krvavitev, edem, edem nog
Haemorrhage, oedema, oedema leg
krvavitev, edem, edem noge
Haemorrhage, oedema, oedema leg
krvavitve, edem, edem nog
Haemorrhage, such as epistaxis and haematuria.
Krvavitev, npr. epistaksa in hematurija
Haemorrhage; haematoma
krvavitev; hematom
Haemorrhagec,d,h
krvavitvec, d. h
Haemorrhaged
krvavitevd
Haemorrhagic
Hemoragična
Haemorrhagic corpus luteum/haemorrhagic ovarian cyst
krvavitev v rumeno telesce/krvavitev v ovarijsko cisto
Haemorrhagic cystitis Haematuria Proteinuria
Hemoragični cistitis Hematurija Proteinurija
Haemorrhagic cystitis**
hemoragični cistitis
Haemorrhagic diathesis
hemoragična diateza
Haemorrhagic disorders
Krvavitve
Haemorrhagic events
Hemoragični dogodki
Haemorrhagic events, including major haemorrhagic and fatal haemorrhages, have occurred in patients taking the combination of dabrafenib with trametinib (see section 4.8).
Pri bolnikih, ki so jemali dabrafenib v kombinaciji s trametinibom, je prihajalo do krvavitev, med katerimi so bile večje krvavitve in krvavitve, zaradi katerih so bolniki umrli (glejte poglavje 4.8).
Haemorrhagic events, including major haemorrhagic events and fatal haemorrhages have occurred in patients taking trametinib as monotherapy and in combination with dabrafenib.
Pri bolnikih, ki so jemali trametinib, bodisi v monoterapiji ali v kombinaciji z dabrafenibom, je prihajalo do krvavitev, med katerimi so bile večje krvavitve in krvavitve, zaradi katerih so bolniki umrli.
Haemorrhagic events, including major haemorrhagic events and fatal haemorrhages, have occurred in patients taking dabrafenib in combination with trametinib.
Pri bolnikih, ki so jemali dabrafenib v kombinaciji s trametinibom, je prihajalo do krvavitev, med katerimi so bile večje krvavitve in krvavitve, zaradi katerih so bolniki umrli.